2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2017
Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias
2015
Moving toward the ideal insulin for insulin pumps
Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Review Of Medical Devices 2015, 13: 57-69. PMID: 26560137, DOI: 10.1586/17434440.2016.1109442.Peer-Reviewed Original ResearchConceptsTime-action profileGlycemic controlInsulin formulationsRapid-acting insulin analoguesPhysiologic insulin profilesOptimal glycemic controlInsulin pump therapyNew insulin formulationsQuality of lifeContinuous glucose monitoringRegular insulinPump therapyInsulin profilesPharmacological advancesDiabetes managementInsulin analoguesInsulin absorptionInsulin pumpGlucose monitoringInsulin deliveryPump systemTherapyInsulinDelivery methodsDiabetes
2014
Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry
Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, Haller MJ, Network F. Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. Pediatric Diabetes 2014, 17: 15-20. PMID: 25330905, DOI: 10.1111/pedi.12231.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryElevated blood pressureBlood pressureClinic registryACE-I therapyReceptor blocker therapyGoal blood pressureDiagnosis of hypertensionPediatric diabetes clinicBlocker therapyBP goalHypertensive childrenUndertreated hypertensionARB therapyAggressive managementCardiovascular riskDiabetes clinicHigher BMIMedical recordsHypertensionReceptor inhibitorsDiabetesTherapyVisits
2013
Insulin pumps in children with T1DM—we told you so
Tamborlane WV, Sherr JL. Insulin pumps in children with T1DM—we told you so. Nature Reviews Endocrinology 2013, 9: 629-630. PMID: 24080733, DOI: 10.1038/nrendo.2013.190.Peer-Reviewed Original ResearchRace, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes
Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood F. Race, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes. Diabetes Technology & Therapeutics 2013, 15: 929-934. PMID: 23869706, PMCID: PMC3817890, DOI: 10.1089/dia.2013.0132.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleHealth Services AccessibilityHealthcare DisparitiesHumansHypoglycemic AgentsInfantInfusion Pumps, ImplantableInsulinInsulin Infusion SystemsMaleMedically UninsuredSocioeconomic FactorsUnited StatesConceptsNon-Hispanic white raceInsulin pump therapyPump therapyPump useWhite raceFirst yearSocioeconomic statusPediatric diabetes centersTime of diagnosisType 1 diabetesPercent of participantsHigher socioeconomic statusAnnual household incomeNew onsetDiabetes CenterCox regressionT1D diagnosisPrivate health insuranceFollowing DiagnosisNumber of childrenTreatment centersMultivariate analysisTherapyType 1Early use
2012
Insulin Therapy in Children and Adolescents
Tamborlane WV, Sikes KA. Insulin Therapy in Children and Adolescents. Endocrinology And Metabolism Clinics Of North America 2012, 41: 145-160. PMID: 22575411, DOI: 10.1016/j.ecl.2012.01.002.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous insulin infusionInsulin therapyBasal-bolus therapyMainstay of treatmentInsulin replacement therapyType 2 diabetesType 1 diabetesDaily injectionsReplacement therapyAnalogue insulinInsulin infusionInsulin secretionBiosynthetic humanTherapyInsulin formulationsNormal patternDiabetesTreatmentChildrenAdolescentsInfusionAimMainstayInsulin
2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original ResearchEffectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study
Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatric Diabetes 2011, 13: 6-11. PMID: 21722284, DOI: 10.1111/j.1399-5448.2011.00793.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented pump therapyA1C valuesSAP groupMDI groupPump therapyA1C targetsSAP therapyHyperglycemic excursionsMultiple daily injection therapyBaseline A1C valuesRisk of hypoglycemiaA1C reductionInjection therapyPediatric patientsGlycemic excursionsGlucose variabilityMDI therapyGlycemic variabilityLower AUC valuesTreatment groupsTherapyCGM studiesDiabetesAUC valuesNew-generation diabetes management: glucose sensor-augmented insulin pump therapy
Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Review Of Medical Devices 2011, 8: 449-458. PMID: 21728731, PMCID: PMC3177536, DOI: 10.1586/erd.11.22.Peer-Reviewed Original ResearchConceptsSensor-augmented insulinSensor-augmented insulin pump therapyCommon chronic disorderInsulin pump therapyContinuous subcutaneous insulin infusion systemsInsulin infusion systemField of diabetesPump therapyGlucose variabilityChronic disordersChallenging diseaseContinuous glucose monitorDelivery of insulinDiabetes managementInfusion systemTherapyInsulin deliveryTechnologic advancesInsulin
2010
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapy
2008
Past, present, and future of insulin pump therapy: better shot at diabetes control
Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Annals Of Global Health 2008, 75: 352-361. PMID: 18729180, PMCID: PMC2562271, DOI: 10.1002/msj.20055.Peer-Reviewed Original ResearchConceptsPump therapyDiabetes controlContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionInsulin pump therapyInsulin infusion therapySubcutaneous insulin infusionType 1 diabetesComplications TrialInfusion therapyInsulin infusionIntensive treatmentPump useTherapyArtificial pancreasContinuous glucose sensorsDelivery systemFindingsSelection criteriaPatientsDiabetesInfusionPancreasNew findings
2007
Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes
Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT, Martin ML, Tamborlane WV. Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes. Diabetes Care 2007, 31: 44-46. PMID: 17909083, DOI: 10.2337/dc07-0737.Peer-Reviewed Original Research
2006
Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Research And Clinical Practice 2006, 74: s112-s115. PMID: 17182301, DOI: 10.1016/s0168-8227(06)70011-0.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSubcutaneous insulin infusionType 1 diabetesInsulin infusionEfficacy of CSIIExcessive weight gainInsulin pump therapyNew insulin analoguesQuality of lifePediatric patientsSevere hypoglycemiaHemoglobin levelsPump therapyTreatment optionsClinical studiesInsulin analoguesWeight gainDiabetesInfusionChildrenRecent studiesSafetyHypoglycemiaPatientsTherapyFulfilling the promise of insulin pump therapy in childhood diabetes
Tamborlane WV. Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatric Diabetes 2006, 7: 4-10. PMID: 16774611, DOI: 10.1111/j.1399-543x.2006.00171.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoring systemContinuous subcutaneous insulin infusion (CSII) treatmentType 1 diabetes mellitusRapid-acting insulin analoguesTreatment of T1DMComplications TrialDiabetes mellitusDiabetes controlGlucose monitoring systemChildhood diabetesFavorable outcomeInsulin analoguesInfusion treatmentInsulin pumpTherapyMinimal riskT1DMDiabetesInsulinTreatmentMellitusHypoglycemiaCSIIRecent introduction
2002
Insulin pump therapy in the 21st century
Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Postgraduate Medicine 2002, 111: 69-77. PMID: 12040864, DOI: 10.3810/pgm.2002.05.1200.Peer-Reviewed Original Research